Big Pharma drug clears regulatory hurdle

The FDA approves Bristol-Myers Squibb (BMY) and Pfizer's (PFE) sNDA for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis for patients who have undergone knee or hip replacement surgery.

In the U.S., 719,000 knee replacement and 332,000 hip replacement surgeries are performed each year.

The product is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs